Document Type : Review Article

Authors

1 Medical Biochemistry Department, Faculty of Medicine, Zagazig University, Egypt

2 Tropical Medicine Department, Faculty of Medicine, Zagazig University, Egypt

3 Clinical Pathology Department, Faculty of Medicine, Zagazig University, Egypt

4 Internal Medicine Department, Faculty of Medicine, Zagazig University, Egypt

10.48309/jmpcr.2024.449561.1150

Abstract

Inflammatory Bowel Disease (IBD) includes Crohn’s Disease (CD), and Ulcerative Colitis (UC), the two main types of IBD. The IBD incidence is rising globally and among the young age. Endoscopy has a principal role in rating IBD mucosal lesions. Though, it is expensive and invasive. MicroRNAs could be included in regulation of particular genes and included in inflammation. Disorders in microRNAs levels might cause disease development. The objective of our study is to investigate the role of microRNA-16 and microRNA- 106a levels as indicators for diagnosis and assessing the IBD activity. The values of miR 16 and miR 106a were measured in plasma from 20 healthy volunteers (group I) and 40 UC patients (group II) and 40 CD patients (group III) by quantitative real time-PCR (qRT-PCR). Endoscopic severity index was calculated based on laboratory and endoscopic findings. Significant upregulation of miR 16 and miR 106a levels in group II and group III than group I. A positive correlation was demonstrated between both miR 16 and miR 106a with endoscopic severity index. ROC curves of miR 16 for detecting UC showed sensitivity and specificity of 92.5 % and 90 % particularly. ROC curves of miR 106a for differentiating active from inactive CD showed sensitivity and specificity of 90 % and 75 % particularrly. both miR 16 and miR 106a could act as promising biomarkers of IBD diagnosis and assessing its activity aiding in its proper management.





Methods: The values of miR 16 and miR 106a were measured in plasma from 20 healthy volunteers (group I) and 40 UC patients (group II) and 40 CD patients. (group III) by quantitative real time –PCR ( qRT-PCR) .Endoscopic severity index was calculated based on laboratory and endoscopic findings .

Results: Significant upregulation of miR 16 and miR 106a levels in group II and group III than group I. A positive correlation was demonstrated between both miR 16 and miR 106a with endoscopic severity index. ROC curves of miR 16 for detection of UC showed sensitivity and specificity of 92.5 % and 90 % particularly. ROC curves of miR 106a for differentiating active from inactive CD showed sensitivity and specificity of 90 % and 75 % particularly.

Conclusion: both miR 16 and miR 106a could act as promising biomarkers of IBD diagnosis and assessing its activity aiding in its proper management .

Graphical Abstract

Circulating microRNA-16 and microRNA- 106a as novel biomarkers in inflammatory bowel disease

Keywords

Main Subjects

[1] M.Z. Cader, A. Kaser, Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation, Gut2013, 62, 1653-1664. [Crossref], [Google Scholar], [Publisher]‎
[2] A.N. Ananthakrishnan, Epidemiology and risk factors for IBD, Nature Reviews Gastroenterology & Hepatology2015, 12, 205-217. [Crossref], [Google Scholar], [Publisher]‎
[3] A. Geremia, P. Biancheri, P. Allan, G.R.Corazza, A. Di Sabatino, Innate and adaptive immunity in inflammatory bowel disease,  Autoimmunity Reviews2014, 13, 3-10. [Crossref], [Google Scholar], [Publisher]‎
[4] V. Annese, M. Daperno, M.D. Rutter, A. Amiot, P. Bossuyt, J. East, M. Ferrante, M. Götz, K.H. Katsanos, R. Kießlich, I. Ordás, European evidence based consensus for endoscopy in inflammatory bowel disease,  Journal of Crohn's and Colitis20137, 982-1018. [Crossref], [Google Scholar], [Publisher]‎
[5] G.A. Calin, M.  Ferracin, A. Cimmino, G. Di Leva, M. Shimizu, S.E. Wojcik, M.V. Iorio, R. Visone, N.I. Sever, M. Fabbri, R. Iuliano, A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia, New England Journal of Medicine2005, 353, 1793-1801. [Crossref], [Google Scholar], [Publisher]‎
[6] W.J. Tremaine, Is indeterminate colitis determinable?,  Current Gastroenterology Reports2012, 14, 162-165. [Crossref], [Google Scholar], [Publisher]‎
[7] J.D. Lewis, The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease, Gastroenterology2011140, 1817-1826. [Crossref], [Google Scholar], [Publisher]‎
[8] Y.M. Shastri, D. Bergis, N. Povse, V. Schäfer, S. Shastri, M. Weindel, H. Ackermann, J. Stein, Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea,  The American Journal of Medicine2008121, 1099-1106. [Crossref], [Google Scholar], [Publisher]‎
[9] A.A. Soubières, A. Poullis, Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease, World Journal of Gastrointestinal Pharmacology and Therapeutics2016, 7, 41. [Crossref], [Google Scholar], [Publisher]‎
[10] J.A. Weber, D.H. Baxter, S. Zhang, D.Y. Huang, K. How Huang, M. Jen Lee, D.J. Galas, K. Wang, The microRNA spectrum in 12 body fluids,  Clinical chemistry2010, 56, 1733-1741. [Crossref], [Google Scholar], [Publisher]‎
[11] D.G. Johnston, M.A. Williams, C.A. Thaiss, R. Cabrera-Rubio, M. Raverdeau, C. McEntee, P.D. Cotter, E. Elinav, L.A. O’Neill, S.C. Corr, Loss of microRNA-21 influences the gut microbiota, causing reduced susceptibility in a murine model of colitis, Journal of Crohn's and Colitis2018, 12, 835-848. [Crossref], [Google Scholar], [Publisher]‎
[12] S.R. Whiteoak, R. Felwick, T. Sanchez-Elsner, J.R. Fraser Cummings, MicroRNAs in inflammatory bowel diseases: paradoxes and possibilities,  Inflammatory Bowel Diseases2015, 21, 1160-1165. [Crossref], [Google Scholar], [Publisher]‎
[13] R. Rameshshanker, N. Arebi, Endoscopy in inflammatory bowel disease when and why, World Journal of Gastrointestinal Endoscopy2012 4, 201. [Crossref], [Google Scholar], [Publisher]‎
[14] S.P. Travis, D. Schnell, P. Krzeski, M.T. Abreu, D.G. Altman, J.F. Colombel, B.G. Feagan, S.B. Hanauer, M. Lémann, G.R. Lichtenstein, P.R. Marteau, Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS), Gut2012, 61, 535-542. [Crossref], [Google Scholar], [Publisher]‎
[15] L. Masi, I.  Capobianco, C. Magrì, I. Marafini, V. Petito, F. Scaldaferri, MicroRNAs as innovative biomarkers for inflammatory bowel disease and prediction of colorectal cancer,  International Journal of Molecular Sciences2022, 23, 7991. [Crossref], [Google Scholar], [Publisher]‎
[16] L. Sun, Y. Han, H. Wang, H. Liu, S.  Liu, H. Yang, X. Ren, Y. Fang, MicroRNAs as potential biomarkers for the diagnosis of inflammatory bowel disease: a systematic review and meta-analysis,  Journal of International Medical Research2022, 50, 3000605221089503. [Crossref], [Google Scholar], [Publisher]‎
[17] S.S. Krishnachaitanya, M. Liu, K. Fujise, Q. Li, MicroRNAs in inflammatory bowel disease and its complications,  International Journal of Molecular Sciences2022, 23, 8751. [Crossref], [Google Scholar], [Publisher]‎
[18] F. Wu, M. Zikusoka, A. Trindade, T. Dassopoulos, M.L. Harris, T.M. Bayless, S.R. Brant, S. Chakravarti, J.H. Kwon, MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2α, Gastroenterology2008, 135, 1624-1635. [Crossref], [Google Scholar], [Publisher]‎
[19] A.  Paraskevi, G. Theodoropoulos, I.  Papaconstantinou, G.  Mantzaris, N. Nikiteas, M. Gazouli, Circulating MicroRNA in inflammatory bowel disease,  Journal of Crohn's and Colitis2012, 6, 900-904. [Crossref], [Google Scholar], [Publisher]‎
[20] K. Schönauen, N. Le, U. von Arnim, C.  Schulz, P. Malfertheiner, A. Link, Circulating and fecal microRNAs as biomarkers for inflammatory bowel diseases,  Inflammatory Bowel Diseases2018, 24, 1547-1557. [Crossref], [Google Scholar], [Publisher]‎
[21] A.  Atanassova, A. Georgieva, Circulating miRNA-16 in inflammatory bowel disease and some clinical correlations–a cohort study in Bulgarian patients, European Review for Medical & Pharmacological Sciences2022, 26. [Crossref], [Google Scholar], [Publisher]‎
[22] T. Tian, Y. Zhou, X. Feng, S. Ye, H. Wang, W. Wu, W. Tan, C. Yu, J. Hu, R. Zheng, Z. Chen, MicroRNA-16 is putatively involved in the NF-κB pathway regulation in ulcerative colitis through adenosine A2a receptor (A2aAR) mRNA targeting, Scientific Reports20166, 30824. [Crossref], [Google Scholar], [Publisher]‎
[23] A. Habib, A. Minisi, M. Awad, A. Essa, A. Khalifa, S. Shehab-Eldeen, Serum microRNA 106 and microRNA 223 as novel biomarkers in inflammatory bowel disease, Medical Journal of Viral Hepatitis2020, 5, 19-24. [Crossref], [Google Scholar], [Publisher]‎
[24] M. Fasseu, X. Tréton, C. Guichard, E. Pedruzzi, D. Cazals-Hatem, C. Richard, T. Aparicio, F.  Daniel, J.C.  Soulé, R. Moreau, Y. Bouhnik, Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease,  PloS One20105, 13160. [Crossref], [Google Scholar], [Publisher]‎
[25] A.M. Zahm, M. Thayu, N.J. Hand, A. Horner, M.B. Leonard, J.R. Friedman, Circulating microRNA is a biomarker of pediatric Crohn disease,  Journal of Pediatric Gastroenterology and Nutrition201153, 26-33. [Crossref], [Google Scholar], [Publisher]‎
[26] R. Duttagupta, S. DiRienzo, R. Jiang, J. Bowers, J. Gollub, J. Kao, K. Kearney, D. Rudolph, N.B. Dawany, M.K. Showe, T. Stamato, Genome-wide maps of circulating miRNA biomarkers for ulcerative colitis,  PloS One, 2012, 7, 31241. [Crossref], [Google Scholar], [Publisher]‎
[27] H. Wang, S. Zhang, Q. Yu, G. Yang, J. Guo, M. Li, Z. Zeng, Y. He, B. Chen, M. Chen, Circulating microRNA223 is a new biomarker for inflammatory bowel disease, Medicine2016, 95, 2703. [Crossref], [Google Scholar], [Publisher]‎
[28] A.  Omidbakhsh, M. Saeedi, M.  Khoshnia, A. Marjani, S. Hakimi, Micro-RNAs-106a and-362-3p in peripheral blood of inflammatory bowel disease patients,  The Open Biochemistry Journal2018, 12, 78. [Crossref], [Google Scholar], [Publisher]‎
[29] K.D. Taganov, M.P. Boldin, K.J. Chang, D. Baltimore, NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses, Proceedings of the National Academy of Sciences2006, 103, 12481-12486. [Crossref], [Google Scholar], [Publisher]‎